Your institution may have access to this item. Find your institution then sign in to continue.
Title
Phase II trial of PTK787/ZK 222584 (vatalanib) administered orally once-daily or in two divided daily doses as second-line monotherapy in relapsed or progressing patients with stage IIIB/IV non-small-cell lung cancer (NSCLC).
Authors
Gauler, T. C.; Besse, B.; Mauguen, A.; Meric, J. B.; Gounant, V.; Fischer, B.; Overbeck, T. R.; Krissel, H.; Laurent, D.; Tiainen, M.; Commo, F.; Soria, J. C.; Eberhardt, W. E. E.